Drug treatment of multidrug-resistant osteoarticular tuberculosis: a systematic literature review

Suárez‐García, Inés; Noguerado, A

doi:10.1016/j.ijid.2012.07.011

Cited by 31 publications

(21 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At present, osteoarticular tuberculosis has been treated according to the standard therapy protocol by antitubercular drugs for a minimum of 8 and 20 months for total chemotherapy. 2 However, longer treatment time resulted in patient noncompliance and critical side effects. 3 It is key for the treatment of osteoarticular tuberculosis to increase local drug concentrations for higher therapeutic efficiencies and lower toxicity for body.…”

Section: Introductionmentioning

confidence: 99%

Development and in vitro characterization of drug delivery system of rifapentine for osteoarticular tuberculosis

Wu¹,

Zuo²,

Hu³

et al. 2015

DDDT

View full text Add to dashboard Cite

The study was to develop and evaluate the rifapentine-loaded poly(lactic acid-co-glycolic acid) (PLGA) microspheres (RPMs) for the treatment of osteoarticular tuberculosis to avoid critical side effects caused by oral regimens of antibiotics or intravenous antibiotics. The RPMs were spherical with rough surfaces, and elevated amounts of rifapentine in the formulation markedly increased the particle size and drug loading, while decreased the size distribution and entrapment efficiency. The highest drug loading and encapsulation efficiency of RPMs were 23.93%±3.93% and 88.49%±8.49%, respectively. After the initial rapid drug release, the release rate gradually decreased, and approximately 80% of the encapsulated rifapentine was released after 30 days of incubation. Moreover, RPMs could effectively inhibit the growth of Staphylococcus aureus. With increasing rifapentine content, the inhibition zones were continuously enlarged while the minimal inhibitory concentration values decreased. These results suggested that RPMs were bioactive and controlled release delivery systems for the treatment of osteoarticular tuberculosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Development and in vitro characterization of drug delivery system of rifapentine for osteoarticular tuberculosis

Wu¹,

Zuo²,

Hu³

et al. 2015

DDDT

View full text Add to dashboard Cite

show abstract

“…The results of prolonged medical treatment coupled with surgery gives satisfactory results in most patients [5]. The few cases reviewed of osteoarticular multidrug-resistant tuberculosis have a good outcome with second-line anti-tuberculous drugs combined with surgery [18].…”

Section: Discussionmentioning

confidence: 99%

Untitled

2016

MOJOR

View full text Add to dashboard Cite

“…No studies have been found assessing amikacin or kanamycin, but other aminoglycosides have a good penetration into synovial fluid and intervertebral discs. [ 11 ]…”

Section: Methodsmentioning

confidence: 99%

Multi-drug resistant tuberculous spondylitis: A review of the literature

Kizilbash¹,

Seaworth²

2016

Ann Thorac Med

View full text Add to dashboard Cite

While tuberculous vertebral osteomyelitis is an ancient scourge, multi-drug resistant-tuberculosis (MDR-TB) is a modern major public health concern. The objective of this study was to review and summarize the data available on MDR-TB spondylitis. An extensive search of the PubMed database was conducted for articles in English relevant to MDR-TB spondylitis by December 2015. Tuberculous spondylitis accounts for 0.5–1% of all TB cases, and it is estimated that there are probably 5000 MDR-TB spondylitis cases each year worldwide. The diagnosis of MDR-TB spondylitis requires a high index of suspicion based on epidemiologic, clinical, and radiologic features. Cultures and susceptibility testing remain the gold standard for the diagnosis of MDR-TB, but this can take several weeks to obtain. Medical treatment is the mainstay of therapy, and ideally, it should be based on drug susceptibility testing. If empiric treatment is necessary, it should be based on drug exposure history, contact history, epidemiology, and local drug resistance data, if available. The total duration of treatment should not be <18–24 months. Clinical, radiographic, and if possible, bacteriologic improvement should be used to assess the treatment success. Surgery should be reserved for neurologic deterioration, significant kyphosis, spinal instability, severe pain, and failure of medical management.

show abstract

Drug treatment of multidrug-resistant osteoarticular tuberculosis: a systematic literature review

Abstract: Osteoarticular MDR-TB is very infrequently reported in the literature. The few cases reviewed suggest that it is possible to achieve a good outcome with second-line anti-tuberculous drugs, and that surgery might be useful for cases in which an optimized medical treatment is not possible.

Cited by 31 publications

References 28 publications

Development and in vitro characterization of drug delivery system of rifapentine for osteoarticular tuberculosis

Development and in vitro characterization of drug delivery system of rifapentine for osteoarticular tuberculosis

Untitled

Multi-drug resistant tuberculous spondylitis: A review of the literature

Contact Info

Product

Resources

About